The latest: Pharmaceutical services outsourcing company WuXi AppTec Co. Ltd. (2359.HK; 603259.SH) reported its revenue rose 71.2% to 8.47 billion yuan ($1.29 billion) in the first quarter, while its operating profit rose 106% to 1.71 billion yuan, according to an announcement late on Monday.

Looking up: The company’s chemistry business was particularly strong for the quarter, with revenue up 102% to 6.12 billion yuan, accounting for 72% of its total, mainly due to an increase in customer volume and the addition of new capacity.

Take Note: Net cash flow from operating activities for the quarter totaled 497 million yuan, down 25.6% from a year earlier, due to a significant increase in material buying to meet growing customer demand.

Digging Deeper: WuXi AppTec is a pharmaceutical outsourcing services provider, covering the entire industry chain from drug discovery to commercialization. It has grown rapidly on big demand from both foreign and domestic drug developers for outsourced R&D and manufacturing services for their activity in the fast-growing China market, and has recorded eight consecutive quarters of revenue growth. The company forecasts that if the Shanghai Covid-19 pandemic is effectively controlled by the end of April, it expects to achieve revenue growth of 63% to 65% in this year’s second quarter, and is confident that it will achieve full-year revenue growth of 65% to 70%.

Market Reaction: WuXi AppTec’s stock rose 3.2% in early trade on Tuesday and closed up 3% at HK$105.9 at the midday break. The shares now trade at the low end of their 52-week range.

Translation by Jony Ho

To subscribe to Bamboo Works free weekly newsletter, click here

Recent Articles

From Delhi risks to a domestic dairy bust

Some Chinese companies are navigating geopolitical headwinds that are pushing them out of India, and others are adapting to a maturing domestic consumer market where even staples like infant formula…
Yan Palace makes bird's nest products

Yan Palace swoops back to profit growth

China’s largest edible bird’s nest brand said its profit rose 20% to 35% in the first half of 2025, returning to bottom line growth despite pressure on revenue Key Takeaways:…